We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
Read MoreHide Full Article
Shares of Vaxart, Inc. (VXRT - Free Report) rallied 33.3% on Tuesday after the company announced positive data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19.
In fact, the stock has skyrocketed 801.6% so far this year against the industry’s decline of 13.6%.
Per the company, several its vaccine candidates were able to generate immune responses after a single dose in all the animals under the studies was tested. Lead vaccine candidates generated anti-SARS CoV-2 antibodies after the first dose.
Importantly, the antibody responses in all vaccinated animal groups were statistically significant compared to the untreated controls. Additional data from the study will decide which candidate will progress into clinical studies.
Vaxart is looking to develop a vaccine candidate that can generate mucosal immune responses in addition to serum antibody responses, which are potentially significant for protection against the deadly COVID-19 infection.
In March 2020, Vaxart entered into a manufacturing agreement with Emergent BioSolutions (EBS - Free Report) wherein the latter will produce the clinical material for the company’s experimental oral vaccine candidates against COVID-19.
Emergent plans to produce bulk cGMP vaccine to help Vaxart begin a phase I clinical study in the second half of 2020.
We note that Vaxart initiated a program to develop vaccine candidates for fighting the novel coronavirus infection in January 2020. The new vaccine candidate will be based on the company’s proprietary oral vaccine platform, VAAST.
With the coronavirus pandemic infecting more than 2.5 million people worldwide and causing more than 175,000 fatalities, several large and smaller pharma/biotech companies are racing ahead to successfully develop a treatment or vaccine to combat the disease.
Earlier this month, small biotech Novavax (NVAX - Free Report) announced that it plans to initiate a phase I study on its coronavirus vaccine candidate, NVX-CoV2373. The study is expected to begin next month.
Meanwhile, Moderna (MRNA - Free Report) , a leading player in the coronavirus vaccine field, already initiated a phase I study on its mRNA-based vaccine candidate to address the deadly COVID-19.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
Shares of Vaxart, Inc. (VXRT - Free Report) rallied 33.3% on Tuesday after the company announced positive data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19.
In fact, the stock has skyrocketed 801.6% so far this year against the industry’s decline of 13.6%.
Per the company, several its vaccine candidates were able to generate immune responses after a single dose in all the animals under the studies was tested. Lead vaccine candidates generated anti-SARS CoV-2 antibodies after the first dose.
Importantly, the antibody responses in all vaccinated animal groups were statistically significant compared to the untreated controls. Additional data from the study will decide which candidate will progress into clinical studies.
Vaxart is looking to develop a vaccine candidate that can generate mucosal immune responses in addition to serum antibody responses, which are potentially significant for protection against the deadly COVID-19 infection.
In March 2020, Vaxart entered into a manufacturing agreement with Emergent BioSolutions (EBS - Free Report) wherein the latter will produce the clinical material for the company’s experimental oral vaccine candidates against COVID-19.
Emergent plans to produce bulk cGMP vaccine to help Vaxart begin a phase I clinical study in the second half of 2020.
We note that Vaxart initiated a program to develop vaccine candidates for fighting the novel coronavirus infection in January 2020. The new vaccine candidate will be based on the company’s proprietary oral vaccine platform, VAAST.
With the coronavirus pandemic infecting more than 2.5 million people worldwide and causing more than 175,000 fatalities, several large and smaller pharma/biotech companies are racing ahead to successfully develop a treatment or vaccine to combat the disease.
Earlier this month, small biotech Novavax (NVAX - Free Report) announced that it plans to initiate a phase I study on its coronavirus vaccine candidate, NVX-CoV2373. The study is expected to begin next month.
Meanwhile, Moderna (MRNA - Free Report) , a leading player in the coronavirus vaccine field, already initiated a phase I study on its mRNA-based vaccine candidate to address the deadly COVID-19.
Vaxart, Inc. Price
Vaxart, Inc. price | Vaxart, Inc. Quote
Zacks Rank
Vaxart currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>